Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Bought by State Street Corp

State Street Corp grew its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 4.4% in the third quarter, HoldingsChannel reports. The fund owned 384,732 shares of the company’s stock after acquiring an additional 16,248 shares during the quarter. State Street Corp’s holdings in Tyra Biosciences were worth $9,045,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of TYRA. Janus Henderson Group PLC purchased a new stake in shares of Tyra Biosciences during the third quarter worth about $24,994,000. Perceptive Advisors LLC boosted its holdings in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after buying an additional 338,208 shares during the last quarter. Ally Bridge Group NY LLC purchased a new stake in Tyra Biosciences during the 2nd quarter worth approximately $4,232,000. Ensign Peak Advisors Inc acquired a new position in shares of Tyra Biosciences during the second quarter valued at approximately $3,047,000. Finally, American Century Companies Inc. lifted its position in shares of Tyra Biosciences by 582.9% in the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after acquiring an additional 145,346 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TYRA has been the subject of several research reports. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. HC Wainwright dropped their target price on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a report on Monday, November 11th. Oppenheimer raised their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Tyra Biosciences Trading Up 4.3 %

Tyra Biosciences stock opened at $14.70 on Friday. The company has a fifty day simple moving average of $17.34 and a 200-day simple moving average of $19.47. The stock has a market cap of $743.86 million, a P/E ratio of -9.13 and a beta of 1.01. Tyra Biosciences, Inc. has a 12-month low of $11.24 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, sell-side analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Alan Fuhrman purchased 9,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the purchase, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at $205,584. This trade represents a 283.67 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nina S. Kjellson sold 27,493 shares of Tyra Biosciences stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the transaction, the director now owns 458,506 shares in the company, valued at approximately $7,592,859.36. This trade represents a 5.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 84,660 shares of company stock worth $1,839,047 in the last quarter. 15.40% of the stock is owned by insiders.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.